LYNPARZA safety checked in BRCA breast cancer survivors

NCT ID NCT05677308

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how often bone marrow suppression occurs in patients with BRCA-mutated, HER2-negative high-risk breast cancer who took LYNPARZA after surgery. It involved 61 participants in Japan. The goal was to monitor side effects in real-world use, not to measure how well the drug prevents cancer from returning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LYNPARZA (olaparib)
What this could lead to: If successful, this study could confirm that LYNPARZA is safe enough to use as an adjuvant treatment to reduce the risk of breast cancer coming back in high-risk patients.
What could go wrong: This is a small, completed study focused on side effects, not on how well the drug works. Results may not apply to all patients, and bone marrow suppression remains a known risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Research Site

Aichi, Japan
Research Site

Akita, Japan
Research Site

Aomori, Japan
Research Site

Chiba, Japan
Research Site

Ehime, Japan
Research Site

Fukui, Japan
Research Site

Fukuoka, Japan
Research Site

Gifu, Japan
Research Site

Gunma, Japan
Research Site

Hiroshima, Japan
Research Site

Hokkaido, Japan
Research Site

Hyōgo, Japan
Research Site

Ibaraki, Japan
Research Site

Ishikawa, Japan
Research Site

Kanagawa, Japan
Research Site

Kochi, Japan
Research Site

Kumamoto, Japan
Research Site

Kyoto, Japan
Research Site

Mie, Japan
Research Site

Miyagi, Japan
Research Site

Nara, Japan
Research Site

Niigata, Japan
Research Site

Numakunai, Japan
Research Site

Okayama, Japan
Research Site

Okinawa, Japan
Research Site

Osaka, Japan
Research Site

Ōita, Japan
Research Site

Saga, Japan
Research Site

Saitama, Japan
Research Site

Shiga, Japan
Research Site

Shimane, Japan
Research Site

Shizuoka, Japan
Research Site

Tochigi, Japan
Research Site

Tokyo, Japan
Research Site

Tottori, Japan
Research Site

Toyama, Japan
Research Site

Wakayama, Japan
Research Site

Yamaguchi, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.